PARP1 and cancer: Therapeutically, these data allow to reinforce the fact that any cancer type, with BRCA1-PALB2-BRCA2 pathway suppressed, may be targeted by inactivation of RAD52. Despite the development of other therapeutic approaches that take advantage of the synthetic lethality concept in cancers carrying BRCAs genes alterations, such as poly-(ADP-ribose) polymerase (PARP) inhibition, this strategy using RAD52 inhibitors to target depleted BRCA-pathway is different [72,73].